Download PDF
Thromb Haemost 2008; 99(05): 963-964
DOI: 10.1160/TH07-12-0717
Case Report
Schattauer GmbH

Safety of bevacizumab in mild haemophilia B

Catherine Lambert
1   Haemostasis and Thrombosis Unit, Brussels, Belgium
,
Véronique Deneys
2   Haemostasis Laboratory, Cliniques universitaires Saint-Luc, Brussels, Belgium
,
Dominique Pothen
1   Haemostasis and Thrombosis Unit, Brussels, Belgium
,
Cedric Hermans
1   Haemostasis and Thrombosis Unit, Brussels, Belgium
› Author Affiliations
Further Information

Publication History

Received 04 December 2007

Accepted 14 March 2008

Publication Date:
30 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Hurwitz H. et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. N Engl Med 2004; 350: 2335-2342.
    CrossrefPubMedGoogle Scholar
  • 2 Kabbinavar FF. et al. Combined analysis of efficacy : the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712.
    CrossrefPubMedGoogle Scholar
  • 3 Kabbinavar FF. et al. Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
    CrossrefPubMedGoogle Scholar
  • 4 Kabbinavar FF. et al. Addition of bevacizumab to bolus 5FU/leucorvin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705.
    CrossrefPubMedGoogle Scholar
  • 5 Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opnin Drug Saf 2006; 5: 553-566.
    PubMedGoogle Scholar
  • 6 Hoff PM. et al. Preliminary results from a phase II study of FOLFIRI plus bevacizumab (Avastin) as firs-tline treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol Gastroenterol Symp. 2006: 252 (Abstract).
    PubMedGoogle Scholar
  • 7 National Cancer Institute Common toxicity criteria manual version 2.. http://www.ctep.cancer.gov/forms/CTCManual_v4_10–4–99.pdf
    PubMed
  • 8 Kretzschmar A. et al. First BEAT Investigators. Incidence of gastro-intestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumour resection: Preliminary results from the first BEAT trial. Proc Am Soc Clin Oncol Gastroenterol Symp. 2006: 248 (Abstract).
    PubMedGoogle Scholar
  • 9 Hambleton J. et al. Safety of low-dose aspirin in a pooled analysis of 3 randomized, controlled trials of bevacizumab with chemotherapy in patients with metastatic colorectal cancer. J Clin Oncol 2005; 23 (Suppl) Abstract 3554.
    CrossrefPubMedGoogle Scholar
  • 10 Hambleton J. et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol 2004; 22 (Suppl) Abstract 3528.
    CrossrefPubMedGoogle Scholar
  • 11 Hurwitz H. et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
    CrossrefPubMedGoogle Scholar
  • 12 Kabbinavar FF. et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer in subject who are not suitable candidates for first-line CPT-11. J Clin Oncol 2004; 22: 3516.
    CrossrefPubMedGoogle Scholar
  • 13 Kozloff M. et al. Safety of bevacizumab among patients receiving first-line chemotherapy for line metastatic colorectal cancer-updated results from a large observational study in the US (BRITE). Proc Am Soc Clin Oncol Gastroenterol Symp. 2006 247. (Abstract).
    PubMedGoogle Scholar